机构地区:[1]首都医科大学附属北京胸科医院,101149 [2]广东省结核病控制中心 [3]天津市结核病控制中心 [4]遵义医学院附属医院 [5]北京结核病控制研究所 [6]解放军第三0九医院 [7]重庆医科大学附属第一医院结核科 [8]沈阳市胸科医院 [9]新乡医学院第一附属医院结核科 [10]河南省疾病预防控制中心结核病预防控制所 [11]黑龙江省结核病防治所 [12]浙江省疾病预防控制中心结核病防治所 [13]哈尔滨市胸科医院 [14]内蒙古自治区第四医院 [15]湖北省荆州市传染病医院 [16]湖北省荆门市疾病预防控制中心结核病防治所 [17]包头市第三人民医院结核科 [18]唐山市第四医院结核科 [19]秦皇岛市第三医院结核科 [20]北京老年医院门诊部 [21]徐州市传染病医院结核科 [22]北京京煤集团总医院结核科
出 处:《中国防痨杂志》2016年第10期850-857,共8页Chinese Journal of Antituberculosis
摘 要:目的评价复治肺结核新方案与复治肺结核标准方案满疗程的疗效及停药后随访3年的复发率,探讨如何提高复治肺结核的治疗成功率,减少失败率和降低复发率。方法本研究采取前瞻性队列研究,分散随机法。国内有22家结核病防治(简称“结防”)机构共同参与,选择确诊的菌阳复治肺结核患者,排除MDR-PTB、XDR-PTB、非结核分枝杆菌肺病、对治疗有影响的并发症和复治个体化组。根据随机号分为3个组:第1组为采用高剂量的复治新标准方案组(简称“高剂量组”,86例);第2组为采用长疗程的复治新标准方案组(简称“长疗程组”,83例);第3组采用复治标准方案(简称“标准方案组”,82例)。评价上述三组满疗程的治疗成功率、不良反应发生率和停药后随访3年的复发率。结果高剂量、长疗程、标准方案组满疗程治疗成功率分别为84.9%(73/86)、73.5%(61/83)和62.2%(51/82),3组差异具有统计学意义(χ^2=11.152,P=0.004);3组治疗失败率分别为4.7%(4/86)、16.9%(14/83)和19.5%(16/82),3组间差异具有统计学意义(χ^2=9.084,P=0.011)。3组胸部病变X线摄影评价的吸收好转率分别为87.5%(70/80)、86.3%(69/80)和74.0%(54/73),3组间比较差异无统计学意义(χ^2=5.912,P=0.052);空洞闭合率分别为28.9%(11/38)、46.5%(20/43)和27.8%(10/36),3组间比较差异无统计学意义(χ^2=3.940,P=0.139);恶化率分别为1.2%(1/80)、1.2%(1/80)和6.8%(5/73),3组间比较差异无统计学意义(确切概率法,P=0.115)。3年累计复发率占随访例数的5.6%(10/177),高剂量组与长疗程组和标准方案组复发率分别为5.6%(4/72)、1.7%(1/59)和10.9%(5/46),3组比较差异无统计学意义�Objective To evaluate the effectiveness of the new regimens and standard regimen for treatment of tuberculosis (TB) among retreatment patients with pulmonary TB, and to explore the methods for improving the treatment success rate and reducing the treatment failure rate and relapse rate of retreatment pulmonary TB cases. Methods It was a prospective cohort study and a disperse randomization method was used. Twenty-two domestic TB control institutions were involved, The diagnosed smear-positive retreatment pulmonary TB patients were enrolled while the patients with multidrug-resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), non- tuberculous mycobacterium (NTM) and complications which might impact the treatment outcomes, as well as the patients who were receiving the individualized treatments, were excluded. All recruited patients were divided into three groups randomly: 86 cases were in group 1 receiving a new treatment regimen with high dose anti-TB drugs (called "high-dose regimen group"), 83 cases were in group 2 receiving a new treatment regimen with prolonged treatment duration (called "long-course regimen group"), and 82 cases were in group 3 receiving a traditional stan- dard treatment regimen for retreatment TB patients (called "standard regimen group"). The treatment effectiveness of the three groups was evaluated through the treatment success rate at the end of treatment, the poor treatment re- sponse rate and the relapse rate within 3-year follow-up after completion of treatment. Results The treatment success rate in the group 1, group 2 and group 3 was 84.9% (73/86), 73.5% (61/83) and 62. 2% (51/82) respec- tively, and there was statistical significance between the three groups (χ^2= 11. 152, P=0. 004). The treatment fail- ure rate in the group 1, group 2 and group 3 was 4.7% (4/86), 16.9M (14/83) and 19.5% (16/82) respectively, and there was statistical significance between the three groups (χ^2 = 9. 084, P= 0. 01
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...